Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Decision Making: P-value Method01:09

Decision Making: P-value Method

The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

Parietal complications after cystectomy: Incisional and parastomal hernia, epidemiology and risk factors.

The French journal of urology·2024
Same author

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study.

Vaccines·2023
Same author

Predominance of <i>BRCA2</i> Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with <i>BRCA1</i> or <i>BRCA2</i> Mutation.

Cancers·2022
Same author

Development and Validation of a Simplified Prognostic Score in SCLC.

JTO clinical and research reports·2021
Same author

Determination of thresholds of risk in women at average risk of breast cancer to personalize the organized screening program.

Scientific reports·2021
Same journal

Checking Genetic Homogeneity Between Two Samples Using Summary Statistics With Application to Mendelian Randomization.

Statistics in medicine·2026
Same journal

A Bayesian Learning Model for Joint Risk Prediction of Alcohol and Cannabis Use Disorders.

Statistics in medicine·2026
Same journal

Reluctant Transfer Learning in Penalized Regressions for Individualized Treatment Rules Under Effect Heterogeneity.

Statistics in medicine·2026
Same journal

Predictor-Assisted Nonparametric Graphical Models With Multivariate Error-Prone Data.

Statistics in medicine·2026
Same journal

Optimizing Treatment Decision Estimation for Right-Censored Survival Data Through Parameter Transfer Learning.

Statistics in medicine·2026
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 8, 2026

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

Robust Bayesian decision theory applied to optimal dosage.

Christophe Abraham1, Jean-Pierre Daurès

  • 1Unité Mixte de Recherche 'Analyse des systèmes et biométrie' Ecole Nationale Supérieure Agronomique de Montpellier, France. abraham@ensam.inra.fr

Statistics in Medicine
|April 2, 2004
PubMed
Summary
This summary is machine-generated.

This study introduces a model for creating utility functions in dose prescription, crucial for optimizing patient treatment strategies. Evaluating decision robustness via utility, not just the decision, enhances medical treatment reliability.

More Related Videos

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Related Experiment Videos

Last Updated: Jul 8, 2026

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Area of Science:

  • Decision theory
  • Medical informatics
  • Biostatistics

Background:

  • Dose prescription requires balancing patient health state and treatment dose.
  • Accurate utility functions are essential for optimal decision-making in medical treatments.
  • Existing models may not fully capture the uncertainty in utility function estimation.

Purpose of the Study:

  • To develop a robust model for constructing utility functions in dose prescription problems.
  • To investigate the sensitivity of decisions to the approximated utility function.
  • To apply the developed methodology to chemotherapy treatment decisions for lung cancer.

Main Methods:

  • Constructed a utility function u(theta,d) based on conditional probabilities modeled by logistic models.
  • Investigated decision sensitivity by constructing a class of utility functions and approximating Bayes actions.
  • Quantified sensitivity by measuring the greatest difference between expected utilities of Bayes actions.

Main Results:

  • Developed a method to approximate utility functions and assess decision robustness.
  • Demonstrated that measuring robustness through utility provides deeper insights than decisions alone.
  • Successfully applied the model to chemotherapy treatment for lung cancer, highlighting its practical utility.

Conclusions:

  • The proposed model offers a framework for robust decision-making in dose prescription.
  • Assessing the sensitivity of decisions to utility functions is critical for reliable medical treatments.
  • This approach enhances the evaluation of treatment strategies, particularly in complex cases like lung cancer chemotherapy.